TIDMCEL
Celadon Pharmaceuticals PLC
25 May 2023
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
West Midlands Mayor Visits Celadon's Cultivation and
Manufacturing Facility
25 May 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the research, cultivation,
manufacturing and sale of breakthrough cannabis-based medicines,
was delighted to welcome Andy Street, the Mayor of the West
Midlands, to its cultivation and manufacturing facility
yesterday.
During his tour around Celadon's 100,000 sq ft facility, the
Mayor was shown the Company's cutting-edge indoor hydroponic
cultivation area, its R&D laboratory and its planned future
expansion areas. He also outlined his support for plans to make the
West Midlands region a leading hub for the manufacturing and
R&D of cannabis-based medicines. At full capacity, Celadon's
facility is expected to produce medicines for around 50,000 UK
patients, bringing hundreds of high-skilled jobs to the West
Midlands region, in areas such as pharmaceutical R&D and
agronomy.
Among those present to meet the Mayor were members of Celadon's
senior management team, including James Short (Chief Executive
Officer); Arthur Wakeley (Managing Director); and Iqbal Gill (Chief
Scientific Officer). Future expansion plans were discussed, with
Celadon emphasising its desire to expand in the West Midlands
region and create the UK's centre of excellence for cannabis-based
medicines.
Celadon is part of the West Midlands' GBP6.5bn full-service
healthcare and life sciences economy . The region's diverse
population of 4.7 million potential trial participants, combined
with excellent connectivity and valuable medtech assets (including
eight local hospitals and 35 regional centres of clinical research
excellence), make the region an ideal location for Celadon's
operations. In addition, the new powers and GBP1.5bn of funding
recently secured as part of the Deeper Devolution Deal, agreed
between the West Midlands Combined Authority and the UK government,
will help the region to realise its potential as home to the future
of cutting-edge life science innovation.
Andy Street, Mayor of the West Midlands, commented:
"We know just how important the healthcare and life sciences
sector is to the future prosperity of the West Midlands' economy,
which is why we've made it one of the key clusters to focus on as
part of our Plan for Growth. I was delighted therefore to have the
opportunity to visit Celadon, which really is at the cutting edge
of cannabis-based medicines and has a key role to play in our
future plans.
"The UK may already have an established golden pharmaceutical
triangle of London, Oxford, and Cambridge - but Celadon's
investment and expansion plans show just how rapidly the West
Midlands is becoming a key player in this sector. I look forward to
continuing to work with them and growing in partnership."
James Short, Chief Executive Officer of Celadon, commented :
"We are proud members of the West Midlands' burgeoning life
science community, supported by leading institutions, such as Queen
Elizabeth Hospital Birmingham and Birmingham Medical School, and
underpinned by the wide-ranging Deeper Devolution Deal.
"Being located in the West Midlands means that we are never more
than a few hours away from ninety per cent of the UK, making it an
ideal location. We are hugely excited to be part of this regional
growth story and remain immensely grateful to Andy and the West
Midlands Growth Company team for being such supportive partners for
our - and the West Midlands' - journey to life-science
leadership."
Figure 1: Andy Street with James Short, CEO of Celadon
Figure 2: Andy Street (right), with James Short, CEO (left) and
Arthur Wakeley, MD (centre)
Figure 3: Andy Street (far left), with Arthur Wakeley, MD
(centre left), Dr Tariq Ali, Deputy Pro-Vice Chancellor at the
University of Birmingham (centre right) and James Short, CEO
(right)
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Jonathan Turner
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums
/
Ibrahim Khalil +44 (0)20 7250 1446
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and sale of
breakthrough cannabis-based medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and manufacturing and an analytical and R&D
laboratory. Celadon's Home Office licence allows for the commercial
supply of its GMP pharmaceutical cannabis product. The Company's
subsidiary, LVL, owns a MHRA conditionally-approved clinical trial
using cannabis based medicinal products to treat chronic pain in
the UK. Celadon also has a minority interest in early-stage
biopharma Kingdom Therapeutics which is developing a licenced
cannabinoid medicine to treat children with Autism Spectrum
Disorder.
For further information please visit our website
www.celadonpharma.co.uk
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFIFSEERIEFIV
(END) Dow Jones Newswires
May 25, 2023 02:00 ET (06:00 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Apr 2024 to May 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2023 to May 2024